Generic drugmaker Perrigo Co. plc (NYSE: PRGO) is buying the Entocort gastroenterology drug from AstraZeneca plc (LON: AZN) for $380 million.

Entocort, launched 2011, is designed to treat patients who have mild to moderate Crohn’s disease, and generated $89 million in sales through the first nine months of 2015. AstraZeneca says the divestiture is part of the company’s strategy to focus on core areas. The purchase also includes the generic rights to Entocort that are currently held by Par Pharmaceuticals.

Subscribe Now

Complete access to real-time information and analysis of news and trends in the industry.

14-Day Free Trial

No credit card required. Complete access to articles, breaking news and industry data.